Questions Remain Unanswered in Treating Stage 1B Grade 3 Endometrial Cancer

David Barrington, MD, obstetrics & gynecology specialist at Ohio State University Comprehensive Cancer Center, discusses the results investigators found in determining treatment patterns and recommendations for patients with endometrial cancer.

Using the National Cancer database, Barrington et al evaluated race, facilities, region, and more to see what factors were most associated with variation in treatment patterns for this patient population. Through examining the many factors, experts concluded that there is a lot of confusion when it comes to managing patients with 1B grade 3 tumors.

Despite this research, more is needed to determine the proper ways to care for this patient population. Experts hope that the more molecular testing is studied, the better oncologists will be able to care for their patients.

Transcription:

0:08 | I think it highlights the fact that there's a lot of confusion out there about what the optimal treatment for 1B grade 3 tumors is. I think we need further study to elucidate what's going to be the proper way to manage these patients moving forward. As we learn more and more about molecular characteristics, that's going to play a large role.

0:33 | Then also, knowing that the guidelines are great and the more specific we can be with guidelines, the greater chance we have of achieving optimal outcomes for a variety of patients in a variety of circumstances and helping to overcome some of that variety in treatment that may not be the best for our patients.

0:58 | We've utilized the data from the database to answer the question about treatment patterns, as well as facility location and differences in outcomes. I think looking with more granular information with a large retrospective cohort could give us some more information. Then, looking to the future clinical trial results that can guide us more on how to change the treatment we recommend.